Impact of 5‐ASA discontinuation in children with ulcerative colitis on biologic therapy: A propensity score‐matched study

Key Points

• To evaluate how stopping 5-ASA affects children with ulcerative colitis undergoing biologic treatment.
• Propensity score matching
• Assessment of clinical outcomes
• Analysis of treatment safety and efficacy
• Discontinuation of 5-ASA linked to worse clinical outcomes
• Maintaining mesalamine shown to be safer
• Anti-TNF therapy effectiveness may decline without 5-ASA